Hopp til innhold
NHI.no
Annonse

Pemfigoid: Årsak

Innhold i artikkelen

Sykdommen skyldes sirkulerende antistoffer (proteiner i blodet) som binder seg til strukturer i overhuden. Det at antistoffene angriper kroppens eget vev, gjør at vi kaller dem autoantistoffer og pemfigoid hører derfor hjemme i gruppen autoimmune sykdommer. Angrepet fra autoantistoffene fører til en betennelse med dannelse av blærer under overhuden. Årsaken til at dette skjer er ikke kjent.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Pemfigoid . Referanselisten for dette dokumentet vises nedenfor

  1. Petronic-Rosic V. Bullous pemphigoid. BestPractice, last updated 11 Dec, 2020.
  2. Chan LS. Bullous penphigoid. Medscape, last updated Jul, 2017.
  3. Walsh SR, Hogg D, Mydlarski PR. Bullous pemphigoid: From bench to bedside. Drugs 2005;65:905-926. PubMed
  4. Langan SM, Smeeth L, Hubbard R. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180. PubMed
  5. Lamb PM, Abell E, Tharp M, et al. Prodromal bullous pemphigoid. Int J Dermatol 2006;45:209-214. PubMed
  6. Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014; 13:477. PubMed
  7. Tran JT, Mutasim DF. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol 2005; 44:942. PubMed
  8. Maity S, Banerjee I, Sinha R et al. Nikolsky's sign: A pathognomic boon. J Family Med Prim Care. 2020 Feb 28;9(2):526-530. PMID: 32318376 PubMed
  9. Leiferman KM. Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid. UpToDate, last updated May 22, 2017. www.uptodate.com
  10. Holsen SD, Johannessen AC. Sykdommer som affiserer hud og munnslimhinne. Tidsskr Nor Lægeforen 2006; 126: 1214-7. Tidsskrift for Den norske legeforening
  11. Chalmers JR, Wojnarowska F, Kirtschig G, et al. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. Health Technol Assess. 2017; 21:1-90. PMID: 28406394 PubMed
  12. James T, Salman S, Stevenson B, et al. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. Clin Immunol 2019; 198: 54-6. pmid:30557620 PubMed
  13. Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389: 1630-8. pmid:28279484 PubMed
  14. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of mayo clinic experience. Mayo Clin Proc 2005;80:41-47. PubMed
  15. Schmidt E, Bröcker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008 Feb;34(1):56-64. PubMed
  16. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol 1999;41:266-268. PubMed
  17. Baum S, Sakka N, Artsi O, et al. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev 2014; 13:482. PubMed
  18. Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008 May;144(5):612-6. PMID: 18490587 PubMed
Annonse
Annonse